Why the U.S. is using its prescription drug price gouging scandal to raise funds for veterans’ benefits


Ars Technic article August 30, 2018 09:29:54The price of a generic version of an expensive and dangerous prescription drug has skyrocketed in recent years, as lawmakers in many states have used the issue to try to raise money for their state’s veterans’ health programs.

A recent report from the Centers for Medicare and Medicaid Services (CMS) found that generic versions of the drug, Risperdal, have increased by about 30 percent since last year.

While the increase has been largely in the U, other countries have seen increases as well.

Last week, Pfizer announced that it would buy the brand from a private company for $300 million.

The move comes amid a growing controversy over the drug’s price and its potential use in the treatment of high cholesterol.

The drug has been linked to the deaths of thousands of people in the United States and has been a frequent target of Republican and Democratic lawmakers who have blamed it for the country’s high rates of heart disease.

The controversy over Risprdal has been particularly hard-hitting because it is the only generic version in the world.

It is not yet clear how the price has increased.

The price of generic Rispeldel has more than doubled over the past decade.

But that has happened on the back of a huge marketing campaign that has included ads on TV, radio, newspapers and billboards that have portrayed the drug as lifesaving and an essential part of the modern healthcare system.

In the past year, Pfiser has paid nearly $1.6 billion to buy the company from Bristol-Myers Squibb, the world’s largest drugmaker.

In February, Pfisers representatives in a press release noted that the company had been “working closely with CMS and the Centers of Medicare and Medicare Services” since 2011 to negotiate a deal that would make the drug cheaper and more affordable for consumers.

The press release went on to say that Pfizer and CMS had “agreed to work together to reach an agreement to lower the price of Risprodal to $60 a pill for all patients, beginning with Medicaid patients.”

The pharmaceutical company also has been able to make other deals with pharmaceutical companies to lower RisProdal prices.

This year, the company agreed to pay a $1 billion price reduction for an off-patent drug called Pembrolizumab.

This deal will allow Pfizer to continue selling Pfizer’s drug, which has been on the market for more than a decade.

The deal also came as the Senate approved a bipartisan bill to provide $15 billion to the Veterans Affairs department to fund the costs of providing care to veterans with chronic diseases.

In response, the Republican-led House of Representatives passed the Veterans Benefits Improvement Act in early August.

It provides for a $15.2 billion infusion in funding for the VA to address the costs associated with the chronic disease burden.

This money will go towards the construction of new VA health care facilities and new care programs for veterans, according to the legislation.

The House approved the VA-wide spending plan by a vote of 228-194.

The Senate voted unanimously by a 217-194 vote to advance the bill, which also includes $8.8 billion for the Department of Defense to address prescription drug shortages.

However, a provision in the legislation that would allow the VA and the Veterans Health Administration to negotiate lower prices for generic versions was stripped from the bill after it was sent to the Senate for a vote.

As the bill passed the House, Republican Senator Lamar Alexander of Tennessee said that it was time to act on prescription drug costs and the VA’s chronic care crisis.

“There’s a very real concern that veterans will be pushed out of the VA,” he told CNN.

“This is a very, very dangerous situation, but it’s also a very important thing that needs to be done.”

Alexander said he hopes to bring the bill to the floor for a full vote within the next two weeks.

The American Medical Association (AMA) and the American Medical Women’s Association (AMSWA) have also criticized the legislation as overly burdensome and unfair to VA hospitals.

The AMA is an industry group that represents the nation’s doctors, and the AMA is the largest health care association in the country.

AMSWA is a group of physicians, nurses and other healthcare professionals that represents more than 5,000 hospitals.

On Tuesday, the group issued a statement criticizing the bill and said that if the bill passes, the VA will face “unprecedented pressures” and that veterans would be left out of these new, expensive services.

“In this situation, the American public is entitled to know that veterans and their families are not excluded from these services,” the statement said.

The legislation was passed in a party-line vote of 219-213, with all Democrats voting for it.

It now heads to the House floor for an up-or-down vote.

pep treatment medications

Related Posts